Differentially expressed genes in adult familial myelodysplastic syndromes

Leukemia

Volumn 18, Issue 3, 2004, Pages 449-459

  Pradhan, A ^a   Mijovic, A ^a   Mills, K ^b   Cumber, P ^c   Westwood, N ^a   Mufti, G J ^a   Rassool, Feyruz V ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c WEST WALES GENERAL HOSPITAL   (United Kingdom)

Author keywords

Familial myelodysplastic syndromes; Gene expression; Macroarray; Subtractive hybridization

Indexed keywords

CD34 ANTIGEN; COMPLEMENTARY DNA; DIFFERENTIATION ANTIGEN; PROTEIN FOS; RAS PROTEIN; TRANSCRIPTION FACTOR; ZINC FINGER PROTEIN; MESSENGER RNA; RNA; TUMOR MARKER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DNA HYBRIDIZATION; DNA LIBRARY; DOWN REGULATION; EXPRESSED SEQUENCE TAG; FAMILIAL DISEASE; FEMALE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOLECULAR EVOLUTION; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUPPRESSION SUBTRACTIVE HYBRIDIZATION; TISSUE SPECIFICITY; UNINDEXED SEQUENCE; ADOLESCENT; AGED; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; IMAGE SUBTRACTION; METABOLISM; MIDDLE AGED; PEDIGREE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; DNA, COMPLEMENTARY; EXPRESSED SEQUENCE TAGS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEDIGREE; RNA, MESSENGER; RNA, NEOPLASM; SUBTRACTION TECHNIQUE; TUMOR MARKERS, BIOLOGICAL;

EID: 1542503846     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403265     Document Type: Article

References (41)

1. Mufti GJ. Chromosomal deletions in the myelodysplastic syndrome. Leukemia Res 1992; 16: 35-41.
2. Fenaux P. Chromosome and molecular abnormalities in myeloclysplastic syndromes. Int J Hematol 2001; 73: 429-437.
3. Zhao N, Lai F, Fernald AA, Eisenbart JD, Espinosa R, Wang PW et al. Human CDC23: CDNA cloning, mapping to 5q31, genomic structure, and evaluation as a candidate tumor suppressor gene in myeloid leukemias. Genomics 1998; 53: 184-190.
4. Miyazato A, Ueno S, Ohmine K, Ueda M, Yoshida K, Yamashita Y et al. Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood 2001; 98: 422-427.
5. Qian Z, Fernald AA, Godley LA, Larson RA, Le Beau MM. Expression profiling of CD34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci USA 2002; 99: 14925-14930.
6. Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler HP. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 2002; 100: 3553-3560.
7. Side L, Taylor B, Cayouette M, Conner E, Thompson P, Luce M et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 1997; 336: 1713-1720.
8. Shannon KM, O'Connell P, Martin GA, Paderanga D, Olson K, Dinndorf P et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994; 330: 597-601.
9. Ho CY, Otterud B, Legare RD, Varvil T, Saxena R, DeHart DB et al. Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2. Blood 1996; 87: 5218-5224.
10. Olopade OI, Roulston D, Baker T, Narvid S, Le Beau MM, Freireich EJ et al. Familial myeloid leukemia associated with loss of the long arm of chromosome 5. Leukemia 1996; 10: 669-674.
11. Grimwade DJ, Stephenson J, De Silva C, Dalton RG, Mufti GJ. Familial MDS with 5q- abnormality. Br J Haematol 1993; 84: 536-538.
12. Mandla SG, Goobie S, Kumar RT, Hayne O, Zayed E, Guernsey DL et al. Genetic analysis of familial myelodysplastic syndrome: Absence of linkage to chromosomes 5q31 and 7q22. Cancer Genet Cytogenet 1998; 105: 113-118.
13. Gao Q, Horwitz M, Roulston D, Hagos F, Zhao N, Freireich EJ et al. Susceptibility gene for familial acute myeloid leukemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q. Genes Chromosomes Cancer 2000; 28: 164-172.
14. Mijovic A, Mufti GJ. The myelodysplastic syndromes: Towards a functional classification. Blood Rev 1998; 12: 73-83.
15. Cameron E, Mijovic A, Herman JG, Baylin SB, Pradhan A, Mufti GJ et al. P15INK4B is not mutated in adult familial myelodysplastic syndromes. Br J Haematol 2002; 119: 277-279.
16. Gaymes TJ, Mufti GJ, Rassool FV. Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer. Cancer Res 2002; 62: 2791-2797.
17. Gallagher AP, Burnett AK, Bowen DT, Darley RL. Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a protein kinase C-dependent process. Cancer Res 1998; 58: 2029-2035.
18. Tohyama K, Tsutani H, Ueda T, Nakamura T, Yoshida Y. Establishment and characterization of a novel myeloid cell line from the bone marrow of a patient with the myelodysplastic syndrome. Br J Haematol 1994; 87: 235-242.
19. Collins SJ. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 1987; 70: 1233-1244.
20. Franz O, Bruchhaus I, Roeder T. Verification of differential gene transcription using virtual northern blotting. Nucl Acids Res 1999; 27: E3.
21. Jamal R, Thomas NS, Gale RE, Linch DC. Variable expression of p16 protein in patients with acute myeloid leukemia without gross rearrangements at the DNA level. Leukemia 1996; 10: 629-636.
22. Diatchenko L, Lau YF, Campbell AP, Chenchik A, Moqadam F, Huang B et al. Suppression subtractive hybridization: A method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci USA 1996; 93: 6025-6030.
23. Kolonics A, Apati A, Nahajevszky S, Gati R, Brozik A, Magocsi M. Unregulated activation of STAT-5, ERK1/2 and c-Fos may contribute to the phenotypic transformation from myelodysplastic syndrome to acute leukaemia. Haematologia (Budap) 2001; 31: 125-138.
24. Padua RA, Guinn BA, Al-Sabah AI, Smith M, Taylor C, Pettersson T et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: A 10-year follow-up. Leukemia 1998; 12: 887-892.
25. Mitra P, Vaughan PS, Stein JL, Stein GS, van Wijnen AJ. Purification and functional analysis of a novel leucine-zipper/nucleotide-fold protein, BZAP45, stimulating cell cycle regulated histone H4 gene transcription. Biochemistry 2001; 40: 10693-10699.
26. Tommerup N, Vissing H. Isolation and fine mapping of 16 novel human zinc finger-encoding cDNAs identify putative candidate genes for developmental and malignant disorders. Genomics, 1995; 27: 259-264.
27. Vissing H, Meyer WK, Aagaard L, Tommerup N, Thiesen HJ. Repression of transcriptional activity by heterologous KRAB domains present in zinc finger proteins. FEBS Lett 1995; 369: 153-157.
28. Chan PK, Chan FY, Morris SW, Xie Z. Isolation and characterization of the human nucleophosmin/B23 (NPM) gene: identification of the YY1 binding site at the 5′ enhancer region. Nucleic Acids Res 1997; 25: 1225-1232.
29. Xie J, Briggs JA, Briggs RC. Human hematopoietic cell specific nuclear protein MNDA interacts with the multifunctional transcription factor YY1 and stimulates YY1 DNA binding. J Cell Biochem 1998; 70: 489-506.
30. Yoneda-Kato N, Look AT, Kirstein MN, Valentine MB, Raimondi SC, Cohen KJ et al. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 1996; 12: 265-275.
31. Yee HT, Ponzoni M, Merson A, Goldstein M, Scarpa A, Chilosi M et al. Molecular characterization of the t(2;5) (p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease. Blood 1996; 87: 1081-1088.
32. Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996; 87: 882-886.
33. Pi D, Kalousek DK. Translocation t(3;5) in acute myelocytic leukemia type M2, Cancer Genet Cytogenet 1986; 20: 171.
34. Smadja N, Krulik M, de Gramont A, Sirinelli A, Dray C, Brissaud P et al. Translocation t(3;5) and acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1986; 20: 173-174.
35. Doggett KL, Briggs JA, Linton MF, Fazio S, Head DR, Xie J et al. Retroviral mediated expression of the human myeloid nuclear antigen in a null cell line upregulates Dlk1 expression. J Cell Biochem 2002; 86: 56-66.
36. Rosenfeld C, List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: Implications for new therapies. Leukemia 2000; 14: 2-8.
37. Verhoef GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 1992; 6: 1268-1272.
38. Darley RL, Hoy TG, Baines P, Padua RA, Burnett AK. Mutant NRAS induces erythroid lineage dysplasia in human CD34+ cells. J Exp Med 1997; 185: 1337-1347.
39. Gallagher A, Darley R, Padua RA. RAS and the myelodysplastic syndromes. Pathol Biol (Paris) 1997; 45: 561-568.
40. Bellini M. Coilin, more than a molecular marker of the cajal (coiled) body. BioEssays 2000; 22: 861-867.
41. Ogg SC, Lamond AI. Cajal bodies and coilin - moving towards function. J Cell Biol 2002; 159: 17-21.